Table 3.
Results of the pairwise meta-analysis.
| Comparison | n | SBP | n | DBP | n | NO | n | ET |
|---|---|---|---|---|---|---|---|---|
| MD (95% CI) | MD (95% CI) | MD (95% CI) | MD (95% CI) | |||||
| TC + AHD vs AHD | 15 | –12.25 (–16.22 to –8.28) | 15 | –7.58 (–9.98 to –5.19) | 3 | 3.05 (–1.32 to 7.43) | 2 | –11.94 (–25.29 to 1.41) |
| BDJ + AHD vs AHD | 11 | –6.92 (–8.70 to –5.14) | 11 | –4.50 (–7.08 to –1.92) | 3 | 4.42 (3.26 to 5.58) | 4 | –9.23 (–10.85 to –7.61) |
| WQX + AHD vs AHD | 3 | –4.10 (–9.39 to 1.19) | 3 | –3.23 (–9.98 to 3.52) | — | — |
SBP: systolic blood pressure; DBP: diastolic blood pressure; NO: nitric oxide; ET: endothelin; AHD: antihypertensive drugs; TC + AHD: Tai Chi plus antihypertensive drugs; BDJ + AHD: Baduanjin plus antihypertensive drugs; WQX + AHD: Wuqinxi plus antihypertensive drugs; MD: mean difference; and CI: credible intervals. The bold values mean that the results are statistically significant.